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a  b  s  t  r  a  c  t
Protein  tyrosine  phosphatase  1b (Ptp1b),  which  represses  leptin  signaling,  is  a promising  therapeutic
target  for  obesity.  Genome  wide  deletion  of  Ptp1b,  increases  leptin  sensitivity,  protects  mice  from  obe-
sity and diabetes,  but alters  cardiovascular  function  by increasing  blood  pressure  (BP).  Leptin-control  of
metabolism  is centrally  mediated  and  involves  proopiomelanocortin  (POMC)  neurons.  Whether  these
neurons  contribute  to  leptin-mediated  increases  in BP  remain  unclear.  We  hypothesized  that  increasing
leptin  signaling  in  POMC  neurons  with  Ptp1b  deletion  will sensitize  the cardiovascular  system  to  leptin
and  enhance  neurogenic  control  of BP.  We analyzed  the cardiovascular  phenotype  of Ptp1b+/+  and  POMC-
Ptp1b−/−  mice,  at baseline  and  after  7 days  of  leptin  infusion  or sympatho-activation  with  phenylephrine.
POMCPtp1b deletion  did not  alter  baseline  cardiovascular  hemodynamics  (BP, heart  rate)  but  reduced  BP
response  to ganglionic  blockade  and  plasma  catecholamine  levels  that  suggests  a decreased  neurogenic
control  of  BP.  In contrast,  POMC-Ptp1b  deletion  increased  vascular  adrenergic  reactivity  and  aortic  -
adrenergic  receptors  expression.  Chronic  leptin  treatment  reduced  vascular  adrenergic  reactivity  and
blunted  diastolic  and  mean  BP  increases  in  POMC-Ptp1b−/−  mice  only.  Similarly  POMC-Ptp1b−/−  mice
exhibited  a blunted  increased  in  diastolic  and  mean  BP accompanied  by  a gradual  reduction  in  adrenergic
reactivity  in  response  to chronic  vascular  sympatho-activation  with  phenylephrine.  Together  these  data
rule  out  our  hypothesis  but suggest  that  deletion  of Ptp1b  in  POMC  neurons  protects  from  leptin-  and
sympatho-mediated  increases  in BP. Vascular  adrenergic  desensitization  appears  as  a protective  mech-
anism  against  hypertension,  and  POMC-Ptp1b  as  a key  therapeutic  target  for the  treatment  of  metabolic
and  cardiovascular  dysfunctions  associated  with  obesity.
ublis©  2015  The  Authors.  P
. IntroductionCentral control of food intake and energy expenditure highly
epends on the activation of the proopiomelanocortin (POMC)
Abbreviations: 5HT, 5-hydroxytryptamine; ACh, acetylcholine; BP, blood pres-
ure; DBP, diastolic blood pressure; Emax, maximum possible effect; Jak-2, janus
inase-2; l-NAME, N-nitro-l-arginine methyl ester; MAP, mean arterial pressure;
OS,  nitric oxide synthase; Phe, phenylephrine; pD2, potency of the agonist (nega-
ive logarithm to base 10 of the half maximal effective concentration, EC50); POMC,
roopiomelanocortin; Ptp1b, protein tyrosine phosphatase 1b; RQ, respiratory quo-
ient (ratio VCO2 to VO2); SBP, systolic blood pressure; Stat3, signal transducer and
ctivator of transcription 3; VO2, oxygen consumption.
∗ Corresponding author at: Physiology Department, CA3147, Medical College of
eorgia, at Georgia Regents University, 1120 15th Street, Augusta, GA 30912, United
tates. Fax: +1 706 721 7299.
E-mail address: ebelindechanteme@gru.edu (E.J. Belin de Chantemèle).
ttp://dx.doi.org/10.1016/j.phrs.2015.10.012
043-6618/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
expressing neurons present in the arcuate nucleus of the hypotha-
lamus [1]. This speciﬁc population of neurons responds to the
adipocyte-derived hormone leptin by decreasing food intake, and
increasing energy expenditure through an elevated sympathetic
nerve activity to the brown adipose tissue [1,2]. In addition to its
contribution to the control of body size, the adipocyte-derived hor-
mone leptin also regulates the cardiovascular function, notably
blood pressure (BP), via central mechanisms increasing sympa-
thetic activity to the kidneys and the vasculature [3,4]. Targeted
disruptions of leptin signaling in POMC neurons blunted leptin-
mediated increase in BP suggesting a role for POMC neurons in
the control of the blood pressure response to leptin [5–7]. In
contrast with the numerous studies centralizing the metabolic
effects of leptin in the POMC neurons, the aforementioned studies
minimized the contribution of POMC neurons to leptin-mediated
control of body weight [5–7]. Hence, whether leptin-mediated
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
2 acolog
c
i
p
P
d
a
l
J
s
s
t
o
a
w
t
l
[
i
b
o
c
c
i
f
P
i
H
c
r
l
t
t
i
w
t
2
2
(
t
v
w
f
t
A
v
U
2
n
O
m
(
s
g
i36 T. Bruder-Nascimento et al. / Pharm
ontrol of the metabolic and cardiovascular functions is central-
zed in POMC-neurons and requires activation of similar signaling
athways remains a subject of debate [8,9]. To investigate whether
OMC-neurons concomitantly controls the anorexigenic and car-
iovascular effects of leptin, we used the unique and contrasting
pproach consisting of increasing leptin signaling in POMC neurons.
Activation of leptin signaling requires leptin binding to its
ong form receptor, which leads to the transphosphorylation of
anus kinase-2 (Jak-2) resulting in the phosphorylation of tyro-
ine residues on the leptin receptor and the activation of the Stat3
ignaling pathway [1]. Leptin signaling is restrained by the pro-
ein tyrosine phosphatase 1b (Ptp1b) that dephosphorylates Jak-2
n the leptin receptor. This particular function confers to Ptp1b
 major role in the control of metabolic function [10,11]. Indeed,
hile increased Ptp1b expression is associated with leptin resis-
ance and obesity [12–14], genome wide deletion of Ptp1b increases
eptin signaling and protects mice from obesity and type 2 diabetes
10,11]. Targeted deletion of Ptp1b in POMC neurons speciﬁcally
ncreased leptin signaling in this neuronal population, elevated
aseline energy expenditure and enhanced the anorexigenic effects
f leptin protecting mice from obesity and diabetes [15], which
onﬁrmed the pivotal role of POMC neurons in leptin-mediated
ontrol of body size and metabolic function [1]. While investigat-
ng whether increasing leptin signaling would affect cardiovascular
unction, our group demonstrated that genome wide deletion of
tp1b increased baseline and BP response to leptin by sensitiz-
ng mice to leptin-mediated increase in sympathetic activity [16].
owever, whether this enhanced leptin-control of the cardiovas-
ular function requires increased leptin signaling in POMC neurons
emains unknown. Here we tested the hypothesis that increasing
eptin signaling in POMC neurons with Ptp1b deletion will sensitize
he cardiovascular system to leptin and enhance neurogenic con-
rol of blood pressure. The role of POMC neurons leptin signaling
n the control of vascular adrenergic reactivity and blood pressure
as investigated in the POMC-Ptp1b deﬁcient mice generated by
he group of Dr. Kendra Bence [15].
. Material and methods
.1. Animals
Mice deﬁcient in Ptp1b in the proopiomelanocortin neurons
POMC Ptp1b−/−) were generated using the cre/ﬂox technique in
he laboratory of Dr. Kendra Bence at the University of Pennsyl-
ania [15]. Ten to twelve week-old male POMC Ptp1b−/− animals
ere compared to their ﬂox/ﬂox control (Ptp1b+/+). All animals were
ed standard mouse chow, and tap water was provided ad libi-
um. Mice were housed in an American Association of Laboratory
nimal Care—approved animal care facility at Georgia Regents Uni-
ersity. Georgia Regents University Institutional Animal Care and
se Committee approved all protocols.
.2. Body composition and energy expenditure
The body composition of a subset of mice was analyzed by
uclear magnetic resonance spectroscopy (EchoMRI) [17]. The
xymax Lab Animal Monitoring System (CLAMS, Columbus Instru-
ents, Columbus, OH) was used to measure oxygen consumptionVO2), respiratory quotient (RQ) (ratio VCO2 to VO2), food con-
umption, feed efﬁciency (calculated as grams of body weight
ained per grams of food consumed over a 3-day period), and activ-
ty as previously described [18].ical Research 102 (2015) 235–244
2.3. In Vivo blood pressure measurement
Radio-telemetry was employed to record arterial pressure and
heart rate (PA-C10, Data Sciences, Saint Paul, Minn) in conscious
POMC Ptp1b−/− and Ptp1b+/+ animals following the protocol
previously described [16,19,20]. Brieﬂy, one week after recov-
ery from surgery, baseline data were recorded for 7 days. Mice
were subsequently treated with either leptin (10 g/d)[16,20]
or phenylephrine (7.2 and 20 mg/kg/day)[21] via subcutaneous
osmotic mini-pumps (ALZET, Cupertino, Calif; model 1007D,
0.5 L/h).
2.4. Indexes of sympathetic activity
Indexes of neurogenic control of BP were obtained by mea-
suring the drop in BP induced by the injection of the ganglionic
blocker mecamylamine (5 mg/kg, i.p.,) [16,20], in conscious mice
instrumented for telemetry.
2.5. Catecholamine levels
Another index of the degree of sympatho-activation of the ani-
mals was  obtained by measuring plasma catecholamine levels
(HPLC, Vanderbilt University metabolic core). Plasma was isolated
from trunk blood collected at the time of euthanasia (decapitation).
A separate set of animals was used for this experiment.
2.6. Vascular reactivity
Vascular function was  analyzed in Ptp1b+/+ and POMC Ptp1b−/−
thoracic aortas following the protocol previously described [16,20].
Brieﬂy, 2 mm long aortic rings were mounted on a wire myo-
graph. Arterial viability was determined with a potassium-rich
solution (40 mmol/L) and vascular contractility was  analyzed
with cumulative concentration-response curves to phenylephrine
(0.1 nmol/L to 10 mol/L), and serotonin (5-hydroxytryptamine,
5HT; 0.1 mol/L to 10 mol/L). Concentration response curves to
phenylephrine were repeated in aortic rings pre-incubated with the
unspeciﬁc nitric oxide synthase (NOS) inhibitor N-nitro-l-arginine
methyl ester (l-NAME; 100 mol/L, for 20 min), to determine the
contribution of the endothelium to the vascular constriction. Con-
strictions to phenylephrine and 5HT are presented as percent of
KCl-induced constriction. KCl-induced contraction is expressed as
tension in millinewtons (mN). Maximal effect (Emax) and the neg-
ative logarithm of the molar concentration producing the half
maximum response of the concentration-response (pD2) were ana-
lyzed.
2.7. Chronic sympatho-activation
Chronic sympatho-activation was  mimicked by treating mice
chronically with the speciﬁc 1-adrenergic receptor agonist
phenylephrine for 7 days, at the doses of 7.2 or 20.0 mg/Kg/day
[21] (subcutaneous osmotic mini-pump).
2.8. Real-time RT-PCR
Total aortic mRNA was extracted (Trizol Plus, Invitrogen, Carls-
bad, Calif), puriﬁed with RNeasy spin columns, and eluted from
the column in 30 L of DEPC-treated water, and the concentration
was established with a NanoDrop 1000 (NanoDrop Technologies,
Wilmington, Del). Complementary DNA was generated by RT-PCR
with SuperScript III (Invitrogen) from 400 ng of total RNA using
random hexamers. Reverse transcription was performed at 50 ◦C
for 50 min; the enzyme was  heat inactivated at 85 ◦C for 5 min, and
real-time quantitative RT-PCR was performed with the SYBR-Green
T. Bruder-Nascimento et al. / Pharmacolog
Table  1
Deletion of Ptp1b in POMC neurons reduces fat content and increases energy
expenditure.
Body composition and energy expenditure
Ptp1b+/+ POMC Ptp1b−/−
Body weight (g) 22.37 ± 0.61 23.60 ± 0.58
Epidydimal fat (g) 2.54 ± 0.18 1.68 ± 0.14*
Lean mass (%) 68.67 ± 0.88 69.67 ± 0.33
Fat  mass (%) 7.14 ± 0.73 3.57 ± 0.42*
VO2 (ml/kg/h) 3.596 ± 176 4.590 ± 190*
RQ (CO2/O2) 0.90 ± 0.01 0.95 ± 0.01*
Activity counts 8993 ± 1923 9883 ± 2757
Food intake (g) 4.76 ± 0.27 4.29 ± 0.45
Feed efﬁciency (BW/FI) 0.065 ± 0.005 0.040 ± 0.005*
Lean and fat mass were measured by Bruker’s minispec whole body composition
analyzer based on TD-NMR; VO2, RQ, activity counts, food intake and feed efﬁciency
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ata are presented as mean ± SEM; N = 6.
* P < 0.05 vs. Ptp1b+/+.
upermix (Bio-Rad Laboratories, Hercules, Calif) and the following
rimers: a1A- adrenergic receptor R: CTGCCATTCTTCCTCGTGAT;
1A- adrenergic receptor F: GGCTGGAGCATGGGTATATG; 1D-
drenergic receptor F: GCTGGTTCCCCTTTTTCTTC; 1D-adrenergic
eceptor R: ATTGAAGTAGCCCAGCCAGA; GAPDH F: AACTTTG-
CATTGTGGAAGG; and GAPDH R: GGATGCAGGGATGATGTT CT
16,20].
.9. Statistical analysis
All data are presented as mean ± SEM. P values less than 0.05
ere considered signiﬁcant. Differences in means among groups
or non-repeated variables were compared by t-test. Differences
n means among groups and treatments, with repeated variables,
ere compared by 2-way ANOVA with repeated measures, when
ppropriate. Tukey and Bonferroni tests were used as the post hoc
est (GraphPad).
. Results
.1. Mice
As reported in Table 1, POMC Ptp1b−/− mice exhibited decreased
ody fat content (lower epididymal fat mass and reduced percent-
ge of body fat), and increased energy expenditure as reﬂected
y elevated oxygen consumption and RQ ratio and reduced feed
fﬁciency, with no change in activity.
.2. Effects of Ptp1b deletion in POMC neurons on BP and heart
ateMeasurements of mean arterial pressure, systolic and diastolic
lood pressure and heart rate, in conscious mice using the radio-
elemetry technique, revealed that deletion of Ptp1b in POMC
eurons did not alter baseline BP nor heart rate (Table 2, Fig. 1).
able 2
eletion of Ptp1b in POMC neurons does not impair baseline cardiovascular
emodynamics.
Ptp1b+/+ POMC Ptp1b−/−
MAP  (mmHg) 119 ± 4 119 ± 3
SBP (mmHg) 138 ± 3 138 ± 1
DBP (mmHg) 103 ± 2 102 ± 2
HR (BPM) 566 ± 12 572 ± 18
AP: Mean arterial pressure; SBP: Systolic blood pressure; DBP: Diastolic blood
ressure; HR: Heart rate. Data are presented as mean ± SEM; N = 6.ical Research 102 (2015) 235–244 237
3.3. Effects of Ptp1b deletion in POMC neurons on sympathetic
activity and adrenergic reactivity
Sympathetic contribution to the control of BP was exam-
ined by measuring BP response to ganglionic blockade, plasma
catecholamine levels, and the vascular adrenergic reactivity. As
reported in Fig. 2A, POMC Ptp1b−/− mice exhibited a blunted BP
response to mecamylamine compared to Ptp1b+/+ mice, a signiﬁ-
cant decrease in plasma norepinephrine levels (Fig. 2B) and a trend
towards a decrease in plasma epinephrine (Fig. 2C).
Previous studies from our group demonstrated that aortic
adrenergic reactivity parallels resistance artery adrenergic reactiv-
ity and inversely correlates with sympathetic tone [16,20]. While
analyzing vascular function, we observed that POMC Ptp1b−/−
mice exhibited an increased vascular adrenergic reactivity reﬂected
by an enhanced sensitivity (pD2: Ptp1b+/+: 6.1 ± 0.2 vs. *Ptp1b−/−:
7.0 ± 0.1, P < 0.05) and maximal constriction to phenylephrine
(Emax, (% of KCl-induced contraction); Ptp1b+/+: 89.6 ± 6.9 vs.
*Ptp1b−/−: 116.4 ± 3.4, P < 0.05) (Fig. 3B). l-NAME was used to
inhibit the buffering effects of NO on vascular contractility. As
shown in Fig. 3A, l-NAME induced a parallel increase in the
vascular constriction to phenylephrine in Ptp1b+/+ and POMC
Ptp1b−/− mice and maintained the initial difference between
groups (Emax: Ptp1b+/+: 154.2 ± 16.1 vs. *Ptp1b-/-: 189.9 ± 8.2 %
of KCl-induced contraction, P < 0.05 and pD2: Ptp1b+/+: 7.9 ± 0.4
vs. *Ptp1b−/−: 8.2 ± 0.2,  P < 0.05, Fig. 3A). Vascular constriction in
response to depolarization (KCL) or serotonin (5HT) was also mea-
sured. POMC Ptp1b deletion did not alter aortic contractility to
either, KCl (Emax (mN); Ptp1b+/+: 0.79 ± 0.04 vs. POMC Ptp1b−/−:
0.74 ± 0.06; NS, Fig. 3B) or serotonin (Emax (% of KCl-induced con-
traction); Ptp1b+/+: 154.7 ± 7.8 vs. POMC Ptp1b−/−: 165.8 ± 8.8;
pD2: Ptp1b+/+: 6.89 ± 0.10 vs. POMC Ptp1b−/−: 6.96 ± 0.11; NS,
Fig. 3C). Quantiﬁcation of 1A and 1D-adrenergic receptor subtypes
expression via real-time RT-PCR revealed that POMC Ptp1b deletion
signiﬁcantly increased 1A and 1D gene expression in aortic tissue
(Fig. 3D).
3.4. Cardiovascular response to chronic leptin infusion
The contribution of POMC neurons to the control of the car-
diovascular response to leptin was investigated in mice submitted
to a chronic leptin treatment. As reported in Fig. 4, POMC Ptp1b
deletion blunted leptin-mediated increases in MAP  and dias-
tolic blood pressure (DBP) despite enhancing leptin-mediated
increase in sympathetic tone (response to ganglionic blockade,
Fig. 4E). Chronic treatment with leptin restored vascular adren-
ergic reactivity to control levels, in POMC Ptp1b−/− mice (Emax,
(% of KCl-induced contraction); Ptp1b−/− vehicle: 115.2 ± 8.5 vs.
*Ptp1b−/− leptin: 88.7 ± 7.6,  P < 0.05) and pD2: (Ptp1b−/− vehi-
cle: 7.2 ± 0.27 vs. Ptp1b−/− leptin: 7.49 ± 0.29), but did not reduce
aortic ring constriction to phenylephrine in Ptp1b+/+ mice (Emax,
(% of KCl-induced contraction); Ptp1b+/+ vehicle: 87,8 ± 12.2 vs.
Ptp1b−/− leptin: 82.9 ± 6.9) and pD2: (Ptp1b+/+ vehicle: 6.20 ± 0.42
vs. Ptp1b+/+ leptin: 6.31 ± 0.29), Fig. 4F).  In addition, chronic leptin
treatment induced a higher l-NAME-mediated increased in vas-
cular adrenergic reactivity (Fig. 4G) as well as a bigger drop in
-adrenergic receptors expression, in POMC Ptp1b−/− mice com-
pared to Ptp1b+/+ mice (Fig. 4H).
3.5. Cardiovascular response to chronic sympathoactivation
To determine whether increasing leptin signaling in POMC neu-
rons would affect cardiovascular response to systemic increases
in sympathetic activity, we raised vascular sympathetic tone by
chronically treating mice with phenylephrine at the doses of 7.2
or 20.0 mg/Kg/day, for 7 days. As reported in Figs. 5 and 6, chronic
238 T. Bruder-Nascimento et al. / Pharmacological Research 102 (2015) 235–244
Fig. 1. POMC Ptp1b deletion preserves mean arterial pressure and heart hate.
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Ptp1b−/−)  mice. Data are presented as mean ± SEM (n = 6–8).
henylephrine treatment signiﬁcantly increased MAP  and DBP in
tp1b+/+ mice, but not in POMC Ptp1b−/− mice. The absence of
igniﬁcant increase in MAP  and DBP in POMC Ptp1b−/− mice was
ssociated with a decreased vascular adrenergic reactivity. Indeed,
ow doses of phenylephrine signiﬁcantly reduced aortic ring sen-
itivity to phenylephrine (pD2; POMC Ptp1b+/+: 8.36 ± 0.3 vs.
OMC Ptp1b−/− treated with Phenylephrine 7.2 mg/kg: 6.40 ± 0.3,
 < 0.05, Fig. 5E), while high doses reduced both aortic sensitivity
pD2; POMC Ptp1b+/+: 8.36 ± 0.3 vs. POMC Ptp1b−/− treated with
henylephrine 20 mg/kg: 6.38 ± 0.1, P < 0.05) and maximal vascular
onstriction to phenylephrine (Emax (% of KCl-induced contrac-
ion): POMC Ptp1b+/+: 127.6 ± 9.3 vs. POMC Ptp1b−/− treated with
henylephrine 20 mg/kg: 75.9 ± 7.6, P < 0.05, Fig. 6E), in POMC
tp1b−/− mice.
. Discussion
The goal of the present study was to determine whether increas-
ng leptin signaling and metabolic sensitivity to leptin via deletion
f Ptp1b in POMC neurons would be accompanied by an enhanced
eptin-control of the cardiovascular system leading to increased
eurogenic control of blood pressure. The main ﬁndings are that
1) targeted deletion of Ptp1b in POMC neurons did not alter base-
ine BP and heart rate but decreased autonomic and presumably
ympathetic contribution to BP, (2) deletion of Ptp1b in POMC neu-
ons protected mice from leptin and sympatho-mediated increases
n BP, and (3) vascular adrenergic reactivity counterbalanced sym-
athetic tone to maintain basal BP. These results conﬁrmed the
ontribution of POMC leptin signaling to the control of BP, but con-
rasted with our initial hypothesis, which suggested that POMCeasured by radio-telemetry for 7 days, in control (Ptp1b+/+) and POMC Ptp1b ko
leptin signaling intervenes to increase neurogenic control of blood
pressure.
To determine whether POMC leptin signaling concomitantly
controls the metabolic and cardiovascular effects of leptin we
investigated the cardiovascular phenotype of the POMC Ptp1b−/−
generated by Dr. Bence’s group [15]. Preservation of the increased
leptin sensitivity in the POMC neurons in the POMC Ptp1b−/− mice
was conﬁrmed by demonstrating that the animals bred in our lab-
oratory exhibited an identical metabolic phenotype as the animals
described in the Banno’s study [15]. Similar decreases in body fat
content and increases in energy expenditure were indeed reported
in our POMC Ptp1b−/− mice (Table 1).
The initial study by Banno et al. [15] demonstrated that targeted
deletion of Ptp1b in POMC neurons recapitulated the metabolic
phenotype of global Ptp1b knockout mice and protected mice from
obesity and diabetes via leptin-dependent mechanism [15,22].
In contrast, the present study showed that POMC Ptp1b deletion
did not recapitulate the cardiovascular phenotype of global Ptp1b
knockout mice [16]. POMC Ptp1b−/− mice did not exhibit ele-
vated baseline BP and heart rate nor did they develop an increased
BP response to leptin, as observed in global Ptp1b Ko mice [16].
Moreover, against all expectations [7,16,23], POMC Ptp1b deletion
reduced neurogenic control of BP. This reduction in neurogenic
control of BP was revealed by reporting a reduced BP response to
ganglionic blockade as well as lower plasma catecholamine lev-
els, in POMC Ptp1b−/− mice. Although indirect, these two indexes
are likely to be the most accurate measurements of baseline
sympathetic activity. Obtaining direct measurements of baseline
sympathetic activity in conscious mice is unfortunately technically
extremely challenging. So far, Hamza and Hall are the only ones
T. Bruder-Nascimento et al. / Pharmacological Research 102 (2015) 235–244 239
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A) Drop in mean arterial pressure induced by ganglionic blockade (mecamylamine
s  mean ± SEM. (n = 6–7). *P < 0.05 vs. Ptp1b+/+.
ho reported such measurements in mice, in a methodological
aper published in 2012 [24]. Although the technique developed
y these authors is extremely powerful, it has not been used by this
roup in their subsequent studies, nor did any other laboratory use
t, which further highlights the challenging aspect of direct mea-
urements of sympathetic activity in conscious mice. The group of
llyn Mark and Kamal Rahmouni [4,23] is one of the rare groups
ith a long lasting expertise in direct sympathetic nerve record-
ng in mice. Their measurements are nevertheless conducted in
nesthetized animals and their technique allows direct accurate
easurements of sympathetic response to a stimulus only. It does
nfortunately not provide a direct accurate recording of baseline
ympathetic activity. In addition, while this technique has been
mployed for numerous studies over the last 15 years, no other lab-
ratory has been able to reproduce their measurements in mice.
easuring the decrease in BP in response to ganglionic blockade
epresents effectively an indirect measurement of the activity of
he autonomic nervous system and theoretically represents the
esponse to an inhibition of both the sympathetic and parasym-
athetic branches of the autonomic nervous system. As basal
arasympathetic nerve activity is the major determinant of heart
ate (basal sympathetic activity has only small or negligible effects)
25] a potent inhibition of the parasympathetic nervous system
hould induce an increase in heart rate. However ganglionic block-
de did not increase heart rate in POMC Ptp1b−/− and Ptp1b+/+,
ut rather decrease it (data not shown). In addition, parasympa-
hetic innervation of the vascular system is extremely limited. All
ogether this minimizes the contribution of the parasympatheticg catecholamine levels.
/Kg i.p). Plasma norepinephrine (B) and epinephrine (C) levels. Data are presented
activity to the decrease in BP in response to ganglionic blockade
and supports the high contribution of the sympathetic nervous sys-
tem. Our measurement have been conducted with the state of the
art techniques and in conscious animals habituated to be handled
daily. We  believe that the experimental approach used in this study
provides the best experimental reﬂection of baseline sympathetic
activity.
The reduction in neurogenic control of BP in POMC Ptp1b−/−
mice contrasts with previous studies demonstrating that disrupt-
ing leptin signaling via deletion of leptin receptors or major players
of the leptin signaling pathway (Stat3, SHP2) in POMC neurons,
abolished leptin-control of BP pressure [5–7]. The reason for this
discrepancy is unclear. Reduced total body adiposity and its con-
sequent trends towards a decrease in circulating leptin levels [15]
could have provided an explanation for the lower baseline sympa-
thetic tone if leptin infusion, in a leptin-sensitized animal, would
have triggered an enhanced BP response. However, the opposite
results have been gathered. This minimizes the contribution of
reduced plasma leptin levels to the decrease in baseline neuro-
genic control of BP. Hence, these data either imply dissociation or
a different sensitivity to leptin of the signaling pathways regulat-
ing the metabolic and cardiovascular effects of leptin at the level of
the POMC neurons. Indeed, while POMC Ptp1b deletion increased
leptin-mediated control of energy expenditure and sympathetic
activity towards the brown adipose tissue [15], our study suggests
a decrease sympathetic tone towards the vasculature for the same
leptin levels. Another potential explanation for the reduced base-
line neurogenic control of BP can be found in the recent study by
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urkayastha et al. [8]. This study demonstrated that obesity- and
ost likely leptin-mediated hypertension depend on the activation
f the transcription factor nuclear factor kappa B (NF-B) and its
pstream regulator kappa B kinase beta (IKK), in POMC neurons.
tp1b is a negative regulator of the IKK/ NF-B [26,27]. There-
ore, we can speculate that deletion of Ptp1b in POMC neurons
ill reduce the activation of the IKK/ NF-B pathway and pre-
ent leptin-mediated increases in BP. Further work is nevertheless
equired to conﬁrm this second hypothesis.
As supported by several pieces of evidence, such as decreased
P response to ganglionic blockade and low circulating NE lev-
ls, POMC Ptp1b deletion reduced neurogenic control of BP
nd attenuated BP response to both leptin and direct vascu-
ar sympatho-activation. Vascular adrenergic reactivity, assessed
t the aortic levels or in resistance artery, inversely correlates
ith indexes of sympatho-activation, and appears to be a key
echanism counterbalancing changes in sympathetic tone and
reventing changes in BP [16,20]. In accordance with our previ-
us studies reporting that leptin-mediated sympatho-activation
owers vascular adrenergic reactivity and decreases vascular -
drenergic receptor expression [16,20], we observed that the
educed sympathetic tone associated with POMC Ptp1b deletion
ncreased vascular adrenergic reactivity and -adrenergic recep-
ors expression via sympatho-mediated mechanisms. Potential
ontributions of the endothelium or of a generalized increase in
he ability of the vessels to constrict, to the increased baselineL), (B) to KCl-induced contractility, and (C) to serotonin (5HT). (D) Mouse aorta
, in control (Ptp1b+/+) and POMC Ptp1b ko (Ptp1b−/−) mice. Data are presented as
vascular adrenergic reactivity was  excluded. Certainly NO synthase
inhibition with l-NAME preserved the increased vascular con-
striction to phenylephrine. Similarly, POMC Ptp1b deletion did not
increase vascular constriction to serotonin and potassium chloride.
This compensatory increase in vascular adrenergic reactivity likely
explains the preserved baseline BP and notably diastolic blood pres-
sure (DBP) in POMC Ptp1b−/− mice, despite reduced neurogenic
control of blood pressure.
Further evidences to support that vascular adrenergic reactivity
counterbalances changes in sympathetic tone to preserve baseline
BP were obtained by demonstrating that leptin-mediated increases
in BP, notably DBP, were blunted by a decrease in vascular adren-
ergic reactivity in POMC Ptp1b−/− mice. Despite exhibiting an
increased BP response to ganglionic blockade, POMC Ptp1b−/− mice
treated with leptin exhibited a reduced vascular constriction to
phenylephrine and a modest, non-statistically signiﬁcant, increase
in MAP  and DBP. On the other hand, chronic leptin infusion did
not reduced vascular adrenergic reactivity and led to a higher, sta-
tistically signiﬁcant, increase in MAP  and DBP, in Ptp1b+/+ mice. In
order to study the direct vascular response to sympatho-activation,
we measured vascular adrenergic reactivity and BP, in response to
chronic phenylephrine treatment, in Ptp1b+/+ and POMC Ptp1b−/−
mice. Consistent with the results from the leptin-treated mice,
simulation of chronic vascular sympatho-activation with phenyle-
phrine dose-dependently reduced vascular adrenergic reactivity
and prevented phenylephrine-induced increase in MAP  and DBP, in
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n vascular adrenergic reactivity and exhibited an increase in MAP
nd DBP in response to chronic phenylephrine infusion, as observed
ith the leptin treatment. Taken together these data indicate
hat POMC Ptp1b deletion sensitized the vasculature to sympatho-
ediated adrenergic desensitization and that POMC neurons play a
ole in the control sympathetic activity to the vasculature. In addi-
ion, these results support our two previous studies [16,20] and mice treated or not with leptin, (G) in presence or not of l-NAME. (H)  Changes in
sented as mean ± SEM (n = 6–8). *P < 0.05 vs. Ptp1b+/+; #P < 0.05 vs. POMC Ptp1b−/−
suggest that the vasculature, through its reactivity to adrenergic
stimuli, contributes to the BP response to leptin, most likely by
regulating total peripheral resistance. The mechanisms whereby
POMC Ptp1b deletion sensitizes the vasculature to -adrenergic
receptor downregulation remains however unclear. As our results
support a crucial role for sympathetic activity in the control of vas-
cular adrenergic receptor expression, we  can speculate that the
reduced baseline sympathetic tone sensitized the vasculature to
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Fig. 5. POMC Ptp1b deletion sensitizes the vasculatures to sympatho-mediated reduction in adrenergic tone and protects from phenylephrine-induced increase in blood
pressure.
Changes in (A) mean arterial pressure, (B) systolic, (C) diastolic blood pressure, and (D) heart rate, induced by 7 days of phenylephrine infusion at the dose of 7.2 mg/kg/day.
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In agreement with our previous work conducted in global Ptp1b
O mice [16] and in obese mice [20], the results of the present study
uggest a predominance of the vascular adrenergic mechanisms
ver the well-described contribution of the renal sympathetic
ctivity [3,4,23], in the long term BP response to leptin. This discrep-
ncy in the mechanisms controlling BP response to leptin might
nd its explanation in the different experimental designs. While all
ur experiments were performed in conscious animals at baselinend POMC Ptp1b−/− mice treated or not with phenylephrine infusion at the dose of
ith phenylephrine; #P < 0.05 vs. POMC Ptp1b−/− without phenylephrine treatment.
and after 7 days of leptin infusion at physiological doses, increases
in renal sympathetic activity in response to leptin were observed
acutely, in anesthetized animals, and after 120 min of leptin infu-
sion at high pharmacological doses only [23]. Although these direct
measurements of renal sympathetic activity are extremely elegant
and well conducted, their physiological relevance still remains to
be established. Neither sodium retention nor BP response to renal
denervation has been measured in animals exhibiting increased
renal sympathetic activity.
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Fig. 6. POMC Ptp1b deletion sensitizes the vasculatures to sympatho-mediated reduction in adrenergic tone and protects from phenylephrine-induced increase in blood
pressure.
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